Biorestorative Therapies

Biorestorative Therapies Inc. provides stem cell collections, storage, and treatment services. It intends to develop a laboratory, performing cellular characterization and culturing, therapeutic outcomes analysis, stem cell-related IP and stem cell collection and storage services. The firm is developing the following scientific programs: brtxDISC, which offers a non-surgical treatment for bulging and herniated discs and addresses the gap between non-invasive and invasive back procedures and ThermoStem, which involves the use of a cell-based, brown adipose tissue construct, treatment for metabolic disease, such as type 2 diabetes, obesity, hypertension, and other metabolic disorders, as well as cardiac deficiencies. Its products are sold under the BRTX-100, ThermoStem and Stem Pearls trademarks. The company was founded on June 13, 1997 and is headquartered in Melville, NY.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioRestorative Therapies reports strong Q3 performance and eyes FDA approvals

BioRestorative Therapies (BRTX) showcased strong performance and promising data for BRTX-100 in Q3 2024.
While challenges like patient enrollment and regulatory hurdles exist, opportunities for growth and market entry are abundant.
With a solid financial foundation, management's confidence, and strategic planning, BRTX is poised for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioRestorative Therapies, Inc. engages in the development of therapeutic products and medical therapies using cell and tissue protocols. Its programs provide quality of care for chronic back pain caused by disc degeneration and metabolic disorders, including obesity and diabetes. The company's initial investigational therapeutic product being called BRTX-100 focuses on treating damage by an autologous stem cell product that uses own stem cells that are harvested, cultured, and then injected directly into the affected disc to start the repair process. BioRestorative Therapies was founded on June 13, 1997 and is headquartered in Melville, NY.

MELVILLE, N.Y., Feb. 07, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (NASDAQ: BRTX), a clinical-stage company focused on stem cell-based therapies, today announced that Lance Alstodt, BioRestorative's Chairman and CEO, along with Francisco Silva, Vice President of Research and Development, have been invited to ring the closing bell at Nasdaq's stock market closing on Monday, February 7th at 4:00 PM ET in celebration of BioRestoriative's uplisting to Nasdaq.

BioRestorative Therapies to Ring Nasdaq Stock Market Closing Bell

Notice of Allowance Grants Protection for Generating Implantable Three-Dimensional Scaffolds

BioRestorative Therapies Announces Notice of Allowance for New Patent Application in Japan and Expansion of ThermoStem® IP Portfolio

MELVILLE, N.Y., Jan. 26, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company" or “BioRestorative”) (NASDAQ: BRTX ), a life sciences company focused on adult stem cell-based therapies, today announced that it has been named by Insights Care Magazine as one of the ten most innovative regenerative medicine companies in 2022 for its work in developing novel cell-based therapeutics. Insights Care is a magazine that showcases companies in the healthcare and biotech industry.

BioRestorative Therapies Named One of Ten Most Innovative Regenerative Medicine Companies in 2022 by Insights Care Magazine

MELVILLE, N.Y., Jan. 11, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company" or “BioRestorative”) (NASDAQ: BRTX ), a life sciences company focused on stem cell-based therapies, today announced that Robert Paccasassi has been appointed Vice President of Quality Assurance/Regulatory Compliance. Mr. Paccasassi will lead quality initiatives through the next phase of the Company's growth as patient enrollment is initiated for the Phase 2 clinical trial to treat chronic lumbar disc disease.

BioRestorative Therapies Announces the Appointment of Robert Paccasassi to Vice President of Quality Assurance/Regulatory Compliance

ClearOne

Flotek Industries

Oragenics

Insiders decided to buy these penny stocks recently The post 4 Top Penny Stocks To Buy Right Now According To Insiders appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

4 Top Penny Stocks To Buy Right Now According To Insiders

MELVILLE, N.Y., Jan. 06, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company" or “BioRestorative”) (NASDAQ: BRTX ), a life sciences company focused on stem cell-based therapies, today announced that Lance Alstodt, its Chief Executive Officer, will present a corporate overview at the H.C. Wainwright BioConnect 2022 Conference, being held virtually from January 10-13, 2022.

BioRestorative Therapies to Present at H.C. Wainwright BioConnect Virtual Conference

MELVILLE, N.Y., Jan. 04, 2022 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company" or “BioRestorative”) (NASDAQ: BRTX ), a life sciences company focused on stem cell-based therapies, today announced that it has been awarded a Small Business Technology Transfer (STTR) Phase I grant for $256,000. The funds will be used specifically to evaluate the therapeutic effects on the Company's hypoxic cultured bone marrow derived mesenchymal stem cells (BRTX-100) after encapsulation with a PEG-peptide hydrogel. The work is being done in collaboration with Dr. Lori Setton, Chair of the Department of Biomedical Engineering at Washington University in St. Louis.

BioRestorative Therapies Awarded an STTR Phase I Grant to Explore the Therapeutic Effects of PEG-Peptide Hydrogel-Encapsulated Hypoxic Bone Marrow Stem Cells

Ambev

Transocean

Check these penny stocks out for your January 2022 watchlist The post Best Penny Stocks to Buy in January 2022? Check These 3 Out appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks to Buy in January 2022? Check These 3 Out

The stock price of BioRestorative Therapies Inc (NASDAQ: BRTX) increased by over 45% pre-market today. This is why it happened.

BioRestorative Therapies Stock (BRTX): Why The Price Surged Today

MELVILLE, N.Y., Dec. 21, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company" or “BioRestorative”) (NASDAQ: BRTX ), a life sciences company focused on adult stem cell-based therapies, today announced it has entered into a Master Service Agreement with PRC Clinical, a contract research organization (CRO) specializing in clinical trial management to conduct BioRestorative's Phase 2 clinical trial.

BioRestorative Therapies Announces CRO Agreement with PRC Clinical for its BRTX-100 Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease

MELVILLE, N.Y., Dec. 21, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company" or “BioRestorative”) (NASDAQ: BRTX ), a life sciences company focused on adult stem cell-based therapies, today announced its Chief Executive Officer, Lance Alstodt, will be featured on the James Hicks “NewMedia Show” on Tuesday, December 21st.

BioRestorative Therapies CEO Interviewing Live on the James Hicks NewMedia Show

MELVILLE, N.Y., Dec. 20, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company" or “BioRestorative”) (NASDAQ: BRTX ), a life sciences company focused on adult stem cell-based therapies, today released the following year-end message.

BioRestorative Therapies, Inc. Releases Year-End Message

MELVILLE, N.Y., Dec. 02, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company" or “BioRestorative”) (NASDAQ: BRTX ), a life sciences company focused on adult stem cell-based therapies, today announced that it has filed ten patent applications related to its BRTX-100 program for treating chronic lumbar disc disease with the United States Patent and Trademark Office (USPTO).

BioRestorative Therapies Announces Filing of Ten Patent Applications Related to its BRTX-100 Program

PRC Clinical to Provide Start-up CRO Services for BRTX-100 Phase 2 Clinical Trial

BioRestorative Therapies Enters into Letter of Intent with PRC Clinical

MELVILLE, N.Y., Nov. 10, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company") (NASDAQ: BRTX ), a life sciences company focused on adult stem cell-based therapies, today announced that it has appointed Robert Kristal to the position of Chief Financial Officer. Mr. Kristal brings an extensive array of strategic and financial markets experience to the Company, including a background in advising global public life sciences companies in corporate finance, operations management systems, and strategic collaborations.

BioRestorative Therapies Appoints Robert Kristal as Chief Financial Officer

MELVILLE, N.Y., Nov. 09, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company") (NASDAQ:BRTX), a life sciences company focused on adult stem cell-based therapies, today announced the closing of the underwritten public offering of 2,300,000 units, each consisting of one share of its common stock and a warrant to purchase one share of its common stock at a per unit price of $10.00. The warrants have a per share exercise price of $10.00, are exercisable immediately, and expire five years from the date of issuance. In addition, the underwriter has partially exercised its option to purchase additional securities by purchasing warrants to purchase up to 345,000 shares of common stock. The aggregate gross proceeds from the offering are approximately $23 million, before deducting the underwriting discounts and commissions and estimated offering expenses payable by the Company. In connection with the offering, on November 5, 2021, the Company's common stock was listed on the Nasdaq Capital Market under the ticker symbol “BRTX”.

BioRestorative Therapies Announces Closing of $23 Million Public Offering

Common stock will begin trading on The Nasdaq Capital Market under the ticker symbol “BRTX” November 5, 2021

BioRestorative Therapies Prices $23 Million Public Offering and Uplisting to the Nasdaq Capital Market

MELVILLE, N.Y., Sept. 23, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“ BioRestorative ” or the “Company”) (OTC: BRTX), a life sciences company focused on stem cell-based therapies, today announced that the Israeli Patent Office has issued BioRestorative a Notice of Allowance for a patent application for its metabolic ThermoStem® program.

BioRestorative Therapies Receives Notice of Allowance for Patent Application in Israel for its Metabolic Program

Issued Patent Grants Protection for an Implantable Scaffold using Brown Adipose Derived Stem Cells and Methods of Use

BioRestorative Therapies Receives Patent in Australia Related to its Off-the-Shelf ThermoStem® Program

Patent Issued Grants Protection for Deriving Brown Adipocytes from Brown Adipose (Fat)-Derived Stem Cells

BioRestorative Therapies Receives Patent in Japan Related to its Off-the-Shelf ThermoStem® Program

MELVILLE, N.Y., Aug. 19, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative” or the “Company”) (OTC: BRTX), a life sciences company focused on stem cell-based therapies, announced today that it has been named one of the Top 10 Spine Device Companies and featured by MedTech Outlook, a leading print and digital magazine that provides details and insights regarding novel and high impact medical technologies. BioRestorative Therapies has been provided with such an honor as part of the annual listing of 10 companies that are at the forefront of providing Spine Device solutions and impacting the industry.

BioRestorative Therapies Awarded One of Top 10 Spine Device Companies by MedTech Outlook

MELVILLE, N.Y., Aug. 09, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”) (OTC: BRTX ), a life sciences company focused on stem cell-based therapies, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission for a proposed underwritten public offering of its securities. This offering will be subject to the registration statement on Form S-1 becoming effective and subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed.

BioRestorative Therapies Announces Filing of Registration Statement for Proposed Public Offering

BioRestorative Therapies invites individual and institutional investors, as well as advisors and analysts, to attend its real-time, interactive presentation at the online Emerging Growth Conference.

BioRestorative Therapies to Present at the Emerging Growth Conference on June 9, 2021

MELVILLE, N.Y., May 10, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (OTC: BRTX ), a life sciences company focused on stem cell-based therapies, today announced that it is initiating expansion of its Melville, New York based research laboratories to include capabilities for the clinical production of the Company's pipeline of clinical and investigational cell therapy candidates.

BioRestorative Therapies Expanding its Cell Therapy Manufacturing Facility

MELVILLE, N.Y., May 03, 2021 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRestorative”) (OTC: BRTX), a life sciences company focused on stem cell-based therapies, today announced that it has filed its Annual Report on Form 10-K for the year ended December 31, 2020 and, as a result, is now current in its SEC periodic filings. The filing of the Form 10-K has resulted in the removal of the “stop sign” from the OTC Markets website with regard to the Company, indicating that BioRestorative now has current public information available.

News for Biorestorative Therapies Stock (BRTX)